| abstract |
Disclosed is a drug for preventing and / or treating synucleinopathies such as Lewy body disease. A structure of the following formula 1, which has an ability to bind to an antibody specific for an epitope of α-synuclein containing the amino acid sequence DMPVDPDN and can induce in vivo formation of an antibody that binds to α-synuclein. Use of a compound having (X 1 ) n X 2 X 3 PVX 4 X 5 X 6 (X 7 ) m (Formula 1), where X 1 , X 3 , X 4 and X 7 are any amino acid residues X 2 and X 6 are selected from the group consisting of aspartic acid (D) and glutamic acid (E), and X 5 is selected from the group consisting of proline (P) and alanine (A). N and m are independently 0 or an integer greater than 0, and include the same polypeptide or fragment thereof as the α-synuclein octamer polypeptide having the amino acid sequence DMPVDPDN Absent.) [Selection figure] None |